In 2015, the pharmacological landscape for HF was revolutionized by the introduction of Sacubitril/Valsartan (commercial name LZ969), an angiotensin receptor-neprilysin inhibitor.[6] Clinical trials conclusively demonstrated its efficacy in reducing all-cause mortality and the rate of HF-related hospitalizations, outperforming traditional ACEIs like enalapril.[7] Moreover, Sacubitril/Valsartan has shown particular promise in attenuating myocardial remodeling, a phenomenon strongly correlated with HF progression. The gene discussed is MME; the disease is hydrops fetalis.